Healio

Endpoints met in phase 2a trial of AB-101a for pediatric atopic dermatitis

Please provide your email address to receive an email when new articles are posted on . AB-101a improved mild to moderate atopic dermatitis in pediatric patients as young as 2 years old. All primary ...
Yahoo Finance

AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9

First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with enrollment continuing Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...
Nature

Significant loss of hepatitis A Ab after allogeneic hematopoietic SCT in pediatric patients

Hematopoietic SCT (HSCT) has been a treatment modality for many diseases over the last decade. Both the innate and specific immunity are impaired after HSCT. Loss of specific immunity against ...
TipRanks on MSN

BioGaia AB Reports Q3 2025 Growth and Strategic Initiatives

BioGaia AB ( ($SE:BIOG.B) ) has shared an update. BioGaia AB reported a 7% increase in net sales for the third quarter of 2025, driven by growth ...
Business Insider

AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9

Research Triangle Park, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, ...